A special key for unlocking the door to targeted therapies of breast cancer

Kristina Lindemann; Nadia Harbeck; Ernst Lengyel; James H Resau

doi:10.1100/tsw.2008.110

A special key for unlocking the door to targeted therapies of breast cancer

ScientificWorldJournal. 2008 Sep 21:8:905-8. doi: 10.1100/tsw.2008.110.

Authors

Kristina Lindemann¹, Nadia Harbeck, Ernst Lengyel, James H Resau

Affiliation

¹ Department of Obstetrics and Gynaecology, Medical Faculty, University of Oslo, Division Akershus University Hospital, Norway. kristina.lindemann@ahus.no

Abstract

Personalized medicine and targeted therapy is the best hope for patients with cancer. C-Met-HGF/SF inhibition may be an effective cancer treatment for ductal carcinoma of the breast as it is expected to be an important signalling target in a large number of malignancies.

MeSH terms

Breast Neoplasms / therapy*
Carcinoma, Intraductal, Noninfiltrating / therapy*
Hepatocyte Growth Factor / therapeutic use*
Humans
Proto-Oncogene Proteins c-met / drug effects*
Proto-Oncogene Proteins c-met / genetics
Receptor, ErbB-2 / metabolism*

Substances

Hepatocyte Growth Factor
Proto-Oncogene Proteins c-met
Receptor, ErbB-2